Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 2/20 | 0.35 |
| ▸ | IDH1 | O75874 | 14/20 | 0.35 |
| ▸ | IDH2 | P48735 | 12/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18459488 | 0.89 | IDH1 (0.41) | FGFR4IDH1IDH2MEN1KMT2A | |
| SCHEMBL18426683 | 0.84 | IDH1 (0.41) | FGFR4IDH1IDH2MEN1KMT2A | |
| SCHEMBL18459591 | 0.84 | FGFR4 (0.38) | FGFR4IDH1IDH2MEN1KMT2A | |
| SCHEMBL24170978 | 0.82 | FGFR4 (0.39) | FGFR4IDH1IDH2MEN1KMT2A | |
| SCHEMBL25538694 | 0.81 | FGFR4 (0.36) | FGFR4IDH1IDH2MEN1KMT2A | |
| SCHEMBL20101835 | 0.79 | IDH1 (0.35) | IDH1IDH2MEN1KMT2A | |
| SCHEMBL18426564 | 0.77 | FGFR4 (0.48) | FGFR4IDH1IDH2MEN1KMT2A | |
| SCHEMBL18459263 | 0.76 | IDH1 (0.40) | FGFR4IDH1IDH2MEN1KMT2A | |
| SCHEMBL31452033 | 0.75 | WEE1 (0.49) | FGFR4IDH1IDH2MEN1KMT2A | |
| SCHEMBL30325018 | 0.75 | FGFR4 (0.36) | FGFR4IDH1IDH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328866-B1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIT USE AS MUTANT IDH1 INHIBITORS | LILLY CO ELI (US) | 2019-10-30 | — | — | EP | disclosed |
| US-10253041-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors | ELI LILLY AND COMPANY (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180118759-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIR USE AS MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY | 2018-05-03 | — | — | US | disclosed |
| US-20180118759-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIR USE AS MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY | 2018-05-03 | — | — | US | disclosed |
| WO-2017019429-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIT USE AS MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY (US) | 2017-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253041-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors | IDH1, IDH3A, IDH3B | FGFR4 383/4885IDH1 1/4885IDH2 4/4885 |
| US-20180118759-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIR USE AS MUTANT IDH1 INHIBITORS | IDH1, IDH3A, IDH3B | FGFR4 383/4885IDH1 1/4885IDH2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.